Another epigenome editing startup launches from a pair of the field’s longtime leaders
A little under 20 years ago, Charlie Gersbach decided he needed to try something else.
The young Georgia Tech grad student started out his career hoping to help patients regenerate injured tissues, but he found pretty much nothing worked. None of the chemical or mechanical or even electric interventions then in vogue yielded much success.
So he turned his attention to an emerging approach: changing the epigenome, or the systems of tags and folds on DNA that govern which genes are expressed and how. And he stuck to it, even as many scientists, enticed by CRISPR and other advances, flocked to genome editing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.